藥(phase II2 completed, ASLAN001, a small-molecule pan-HER inhibitor)
星國創新藥公司 想來台上市 2013-10-12 01:51 工商時報 【記者杜蕙蓉／台北報導】生技市場活絡，吸引外商爭相來台掛牌，新加坡創新藥開發公司ASLAN規畫來台上市，該公司最近完成第二輪增資，成功募得美金2,200萬元，參與團隊包括千驥創投、晨興創投和新陳創投等。ASLAN原本投資團隊包括BioVeda Capital和 Sagamore Bioventures，這次新增的投資夥伴中，香港晨興是亞洲最大生技創投集團之一；而新陳創投則是安成藥董事長陳志明個人投資，資本規模1億美元；加上來自美國的千驥創投，也讓ASLAN的股東背景備受矚目。ASLAN表示，本次募得資金將用來進行臨床中的新藥開發，包括作用在胃癌的廣泛性表皮因子受體抑制劑ASLAN001，該藥物現正執行多國多中心的第二期b階段臨床人體試驗 （phase IIb），且已被證實有正面效果的二期試驗結果。此次募資也有助於ASLAN與其他藥廠建立授權合作關係。ASLAN的執行長Carl Firth博士表示，該公司未來至少可再完成5個試驗，以達到概念驗證（POC）的目的。千驥創投的董事長兼管理合夥人Jun Wu也表示，這三年ASLAN展現取得授權方面的卓越能力，同時透過創新和高效率的策略，將這些新的化合物發展到更具價值的階段。ASLAN主要業務係為全球市場研發創新的藥物。目前總部設立在新加坡，在台北亦設有辦公室。營運模式為自跨國大藥廠取得腫瘤和發炎相關疾病尚未進入臨床試驗，或於早期臨床試驗階段的新藥授權，並透過其在亞洲的高品質及高效率發展資源，將這些新藥物開發至較後期的臨床試驗。該公司目前已有3個藥物在臨床試驗發展階段。
Updated on 28 May 2013 Aslan Pharma's phase II clinical trial with pan-HER inhibitor Aslan001 in gastric cancer reduced cell proliferation in gastric tumours that were either coexpressing EGFR and HER2 or that were HER2 amplified for gastric cancer patients - Aslan Pharma's phase II clinical trial with pan-HER inhibitor Aslan001 in gastric cancer reduced cell proliferation for Aslan rheumatoid arthritis drug A*Star identifies gastric cancer trigger ASLAN announces global license agreement with Almirall Singapore: Aslan Pharmaceuticals has revealed the results of its phase II clinical trial with Aslan001, a small-molecule pan-HER inhibitor, in gastric cancer. Aslan001 reduced cell proliferation in gastric tumors that were either coexpressing EGFR and HER2 or that were HER2 amplified. The pan-HER inhibitor was invented by Array BioPharma and licensed to Aslan in 2011. The phase II, open-label, multicenter study was conducted at Seoul National University Hospital, South Korea, and was designed to evaluate the biological activity of Aslan001 in patients with recurrent/metastatic gastric carcinoma whose tumors were HER2 amplified or coexpressing EGFR and HER2. The 23 patients, who had previously failed on one or more rounds of chemotherapy and, where eligible, trastuzumab, each received 500mg of Aslan001 orally twice daily as monotherapy for 28 days. Tumor biopsies taken before and after treatment were analysed using immunohistochemistry. In this heavily pretreated population, Aslan001 led to a downregulation of signalling pathways responsible for cell proliferation, and a reduction in cell survival and cell proliferation. Toxicities observed were consistent with other drugs in this class and the previously reported profile of this compound. Aslan intends to begin a randomized phase IIb study in gastric cancer and is exploring the use of Aslan001 in other indications. Dr Alan Barge, chief medical officer, Aslan, said that, "This is the first time a drug has shown activity in this patient population. The burden of gastric cancer is particularly severe in Asia. It is the most prevalent cancer in males in China, where it is estimated to affect over half a million people."
ASLAN Pharmaceuticals secures US$22M in Series B financing led by Cenova Ventures (Ref: ASLAN Pharmaceuticals) October 10th, 2013 Singapore, 10 October 2013 – ASLAN Pharmaceuticals Pte Ltd announced today the completion of a Series B financing raising US$22 million. The financing was led by Cenova Ventures and included other new investors Morningside Group and XinChen Ventures. Existing investors BioVeda Capital and Sagamore Bioventures also participated in the round.Proceeds from the Series B will be used to fund ongoing clinical development of ASLAN's portfolio, including the phase 2b program for ASLAN001, a small-molecule pan-HER inhibitor being developed for gastric cancer that showed positive data in a phase 2 study completed earlier this year. The financing will also support the licensing of additional compounds in 2013 and 2014. "We are proud to have assembled such a strong group of investors from China, Taiwan and the US that can support the development of our portfolio through efficient and high quality clinical centres in the region," said Dr Carl Firth, CEO of ASLAN. "This round will allow us to complete at least five further studies and deliver robust proof of concept data on several of our programs." Jun Wu, Chairman and Managing Partner at Cenova Ventures said, "In the space of three years, ASLAN has demonstrated their ability to inlicense and progress novel compounds through creative and efficient development strategies. Though several companies have attempted similar models, ASLAN is the first to execute successfully, due largely to its team and network of partners."
About ASLAN ASLAN Pharmaceuticals is a specialty pharmaceutical company that develops novel medicines for global markets, headquartered in Singapore. ASLAN licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology and inflammation diseases, and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. ASLAN currently has 3 drugs in clinical development, with the lead compound entering phase 2b for gastric cancer.
About Cenova Cenova Ventures, founded in 2010 and located in Shanghai, is dedicated to China life sciences and healthcare investment. Cenova primarily focuses on emerging and growing companies with significant market potential in China life sciences sectors, including pharmaceuticals, biotech, medical devices, diagnostics, and healthcare services. The Cenova Venture Fund is managed by seasoned life science investment professionals, and the investment team combines experiences of successful venture start-up and venture investment, management of pre- and post-IPO companies, with proven capabilities to leverage global perspectives, local experiences and network to develop and implement business strategies that best fit specific situations in China.
No comments:
Post a Comment